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Abstract
Background: Uremic toxins are emerging as important, non-traditional cardiovascular risk factors in chronic kidney disease
(CKD). P-cresol has been defined as a prototype protein-bound uremic toxin. Conjugation of p-cresol creates p-cresylsulfate
(PCS) as the main metabolite and p-cresylglucuronide (PCG), at a markedly lower concentration. The objective of the
present study was to evaluate serum PCG levels, determine the latter’s association with mortality and establish whether the
various protein-bound uremic toxins (i.e. PCS, PCG and indoxylsulfate (IS)) differed in their ability to predict mortality.
Methodology/Principal Findings: We studied 139 patients (mean 6 SD age: 67612; males: 60%) at different CKD stages
(34.5% at CKD stages 2–3, 33.5% at stage 4–5 and 32% at stage 5D). A recently developed high-performance liquid
chromatography method was used to assay PCG concentrations. Total and free PCG levels increased with the severity of
CKD. During the study period (mean duration: 7796185 days), 38 patients died. High free and total PCG levels were
correlated with overall and cardiovascular mortality independently of well-known predictors of survival, such as age,
vascular calcification, anemia, inflammation and (in predialysis patients) the estimated glomerular filtration rate. In the same
cohort, free PCS levels and free IS levels were both correlated with mortality. Furthermore, the respective predictive powers
of three Cox multivariate models (free PCS+other risk factors, free IS+other risk factors and free PCS+other risk factors) were
quite similar - suggesting that an elevated PCG concentration has much the same impact on mortality as other uremic
toxins (such as PCS or IS) do.
Conclusions: Although PCG is the minor metabolite of p-cresol, our study is the first to reveal its association with mortality.
Furthermore, the free fraction of PCG appears to have much the same predictive power for mortality as PCS and IS do.
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Introduction
Kidney failure is characterized by the gradual accumulation of
several uremic retention compounds, some of which result from
the degradation of proteins and amino acids [1–4]. When these
compounds interact with biological functions, they are referred to
as uremic toxins. In particular, protein-bound uremic compounds
have recently received much attention [3,5]. In the last decade,
emerging data suggested that these solutes can cause several
biological and physiologic alterations in a uremic setting [1,6]. P-
cresol (the precursor of p-cresylsulfate (PCS) and p-cresylglucur-
onide (PCG)) is mainly generated as an end product of tyrosine
biotransformation by anaerobic intestinal bacteria [7,8]. During
passage through the colonic mucosa and liver, sulfatation and
glucuronidation generates PCS (as the most preponderant
metabolite) and PCG (at markedly lower concentrations) [9].
Various in vitro studies have shown that PCS causes endothelial
damage and exerts a pro-inflammatory effect [6,10] - in contrast to
the mother compound p-cresol, which was shown to have an
immunosuppressant effect [11]. However, to the best of our
knowledge, the only data on the biological impact of PCG were
reported recently by Meert et al [12]. The lack of studies on PCG
may be due to its non-availability for purchase, the difficulty of its
chemical preparation, the low presumed concentrations in vivo
(based on indirect determinations) and the absence of a reliable
determination method until recently [9]. On the basis of the in vitro
experiments performed by Meert et al [12], it appears that PCG
per se has no effect on leukocyte oxidative burst activity; however,
when PCG was combined with PCS, a synergistic, cumulative
leukocyte activating effect was observed [12].
We and others have demonstrated that total and free PCS
serum levels (i) are elevated in late-stage CKD [13] and correlate
with the glomerular filtration rate (GFR) in predialysis patients
[14]. Free PCS was also found to be a predictor of survival in an
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analysis of both dialyzed and non-dialyzed CKD patients [14,15].
We recently studied indoxylsulfate (IS, a protein-bound uremic
toxin that results from the metabolism of dietary tryptophan) and
found that it may be involved in the high incidence of vascular
disease and mortality observed in CKD patients [16].
However, there are no published data on the respective impact
of total and free PCG levels on outcomes in CKD patients. Even
though PCG is a p-cresol conjugate with a relatively low total
concentration, we decided to assess the clinical implications of the
levels of this compound in CKD patients - especially since the free
concentration (which is presumably the biologically active one) is
quite similar to that of PCS [12]. Therefore, the objective of the
present study was to evaluate the serum levels of PCG in a cohort
of patients at different CKD stages. In addition, we sought to
assess the link between PCG levels and overall and cardiovascular
mortality. Lastly, since the impact of PCS and IS on mortality
have already been evaluated in the same cohort, we compared the
respective predictive powers of three different Cox models: free
PCS+other risk factors, free IS+other risk factors and free
PCG+other risk factors.
Materials and Methods
Ethics Statement
The study was conducted according to the principles of the
Declaration of Helsinki and in compliance with International
Conference on Harmonization/Good Clinical Practice regula-
tions. Before the start of the study, patients were provided with
comprehensive study information and all procedures were
approved by a local investigational review board (Comite´ de protection
des Personnes Nord-Ouest II, approval number 06H3) and the French
healthcare authorities. All patients gave their written informed
consent.
Patient Selection
Over an 18-month period (from January 2006 to June 2007), a
total of 150 Caucasian, prevalent CKD patients were recruited
from the Nephrology Department’s outpatient clinic at Amiens
University Hospital.
Included patients had to be over the age of 40, with a confirmed
diagnosis of CKD (defined as being on hemodialysis or having two
previous, estimated creatinine clearances (calculated according to
the Cockcroft and Gault formula) ,90 ml/min/1.73 m2, with an
interval of 3 to 6 months). Stage 5D CKD patients had been on
Figure 1. Serum levels of free p-cresylglucuronide as a function of CKD stage 2, 3, 4, 5 and 5D. *p,0.0001. The dotted line indicates the
reference value for healthy subjects (0.03560.003 mg/dL).
doi:10.1371/journal.pone.0067168.g001
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chronic hemodialysis three times a week for at least 3 months. The
exclusion criteria consisted of the presence of chronic inflamma-
tory disease, atrial fibrillation, complete heart block, abdominal
aorta aneurysm, the presence of an aortic and/or femoral artery
prosthesis, primary hyperparathyroidism, kidney transplantation
and any acute cardiovascular event in the 3 months prior to
screening for inclusion. The 139 patients who met all the inclusion
criteria and none of the exclusion criteria and had available serum
PCS and PCG quantification results were included in the present
analysis.
Study Protocol
All patients were hospitalized for the day in order to perform
laboratory blood tests, blood pressure measurements, a pulse wave
velocity (PWV) determination, a lateral lumbar X-ray and a
multislice spiral computed tomography (MSCT) scan. For a given
patient, all examinations were performed between 9am and 2pm
on the same day. Hemodialysis patients were seen on a dialysis-
free day or, if this was not possible, the morning before the dialysis
session. A patient interview focused on comorbidities, the personal
disease history and (in particular) any previous vascular events.
The patients’ medical files were reviewed in order to identify and
record any concomitant medications. For descriptive purposes,
patients who reported current or past use of insulin and/or orally
administered hypoglycemic drugs were considered to be diabetics.
Previous cardiovascular disease was defined as a history of any of
the following events: myocardial infarction, stroke, heart failure,
angina pectoris, peripheral artery disease and any surgical
procedure or percutaneous transluminal angioplasty because of
vascular disease.
Laboratory Tests
Blood samples were collected in the morning, before the other
investigations were undertaken. Selected assays were performed
after the samples had been frozen and stored at 280uC. Serum
calcium, phosphate, albumin, cholesterol, hemoglobin, creatinine
(Scr) and C-reactive protein levels were assayed in an on-site
biochemistry laboratory using standard auto-analyzer techniques
(the Modular IIPH system, Roche Diagnostics, Basel, Switzerland).
Serum intact PTH (iPTH 1–84) was determined in a chemilumi-
nometric immunoassay (Liaison N-tact PTH CLIAH, Diasorin,
Stillwater, USA). The concentrations of PCS and PCG were
determined with high-performance liquid chromatography
(HPLC) as described recently using a Waters Alliance 2695 device
(Waters, Zellik, Belgium) connected to a Waters 2475 fluorescence
detector. To measure the total serum concentration, samples were
diluted 1 to 6 with HPLC-grade water and then heated at 95uC for
30 minutes. After cooling (10 minutes on ice), samples were filtered
through a CentrifreeH filter (Millipore, Billerica, MA). The
ultrafiltrate was injected onto Ultrasphere ODS column
(15064.6 mm, 5 mm particle size, Beckman Instruments, Full-
erton, CA) with an Ultrasphere ODS guard column (4564.6 mm,
Figure 2. Logarithmic regression curves. The relationship between log-normalized free p-cresylglucuronide serum levels and the estimated
glomerular filtration rate for patients at CKD stages 2 to 5; r2 = 0.34, p,0.0001 (n = 96).
doi:10.1371/journal.pone.0067168.g002
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Table 1. Clinical and demographic characteristics of the study population.
Free p-cresylglucuronide
All n =139 #0.041 mg/dL n=70 .0.041 mg/dL n=69 p
Age, years 67612 68612 66613 0.5
Male gender, n (%) 84 (60) 45 (63) 39 (57) 0.5
Body mass index (kg/m2) 2866 2966 2766 0.02
Diabetes mellitus, n (%) 59 (42) 31 (44) 28 (41) 0.9
Smoking habit, n (%) 56 (41) 29 (41) 27 (39) 0.9
Presence of CVD, n (%) 43 (31) 18 (26) 25 (36) 0.1
Systolic arterial pressure (mmHg) 153626 152624 156629 0.4
Diastolic arterial pressure (mmHg) 81612 82611 81613 0.9
Lipid-lowering therapy n (%) 83 (60) 46 (65) 37 (56) 0.2
Antihypertensive drugs n (%) 125 (90) 66 (94) 59 (85) 0.2
CKD stage, n (%) ,0.0001
2 12 (8) 11 (15) 1 (17)
3 37 (26.5) 33 (46) 4 (7)
4 37 (26.5) 21 (30) 16 (23)
5 10 (7) 2 (17) 8 (12)
5D 43 (32) 5 (7) 38 (55)
Aortic calcification
score on CT,%
3.063.0 (1.9) 2.362.5 (1.4) 3.663.3 (2.6) 0.01
Aortic calcification
score on X-ray, scale 0–24
6.366.6 (4.5) 4.565.8 (3.0) 7.666.9 (6.0) 0.008
PWV, m/s 14.863.8 14.463.6 14.764 0.6
Data are expressed as means 6 SD and (median) for variables with a non-Gaussian distribution or, for binary variables, the number (frequency). CVD: cardiovascular
disease; CKD: chronic kidney disease; CT: computed tomography; PWV: pulse wave velocity.
doi:10.1371/journal.pone.0067168.t001
Table 2. Biochemical characteristics of the study population.
Free p-cresylglucuronide p value
All n= 139 #0.041 mg/dL n=70 .0.041 mg/dL n=69 All n =139
Calcium, mMol/L 2.360.18 2.360.14 2.360.22 0.4
Phosphate, mMol/L 1.360.46 1.260.37 1.460.51 0.005
Intact PTH, pg/mL 1376138 (85) 102699 (65) 1756162 (121) ,0.0001
Albumin, g/L 3866 3867 3766 0.1
C-reactive protein, mg/L 10.7623 (3.5) 8.9616 (2.5) 14630 (4.0) 0.2
Hemoglobin, g/dL 12.061.7 12.761.7 11.561.6 ,0.0001
GFR-epi1, mL/min/1.73 m2 35619 41618 23614 ,0.0001
Total cholesterol, mMol/L 4.961.2 5.061.1 4.861.2 0.2
LDL cholesterol, mMol/L 2.760.9 2.760.9 2.660.9 0.4
Triglycerides, mMol/L 2.061.3 2.061.5 2.061.1 0.7
Free p-cresylsulfate, mg/dL 0.2660.51 (0.051) 0.0260.02 (0.02) 0.5160.64 (0.26) ,0.0001
Free indoxylsulfate, mg/dl 0.0860.09 (0.038) 0.0460.01 (0.037) 0.1360.12 (0.08) ,0.0001
Free p-cresylglucuronide, mg/dL 0.2760.54 (0.041) 0.0360.005 (0.028) 0.5360.69 (0.22) NA
Total p-cresylglucuronide, mg/dL 0.2960.54 (0.046) 0.0360.008 (0.03) 0.5860.75 (0.25) ,0.0001
p-cresylglucuronide, % binding 9.367.3 (8.1) 7.366.9 (6.9) 11.567 (10.6) ,0.0001
Data are expressed as means 6 SD and (median) for variables with a non-Gaussian distribution. PTH: parathyroid hormone; GFR: glomerular filtration rate; LDL: low-
density lipoprotein.
1calculated for patients at CKD stages 2 to 5 (n = 96).
doi:10.1371/journal.pone.0067168.t002
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5 mm article size, Beckman Instruments). To determine the free
fraction, untreated serum samples were filtered through a
CentrifreeH prior to heating. Reference values for total PCS and
free PCS in healthy subjects were 0.27560.160 mg/dL and
0.00860.009 mg/dL, respectively. Reference values for total PCG
and free PCG in healthy subjects were 0.03560.003 mg/dL and
at the detection limit, respectively. To assay for serum IS, samples
were deproteinized by heat denaturation and analyzed by reverse-
phase, high-performance liquid chromatography. The serum
concentrations were then determined by fluorescence detection
(excitation: 280 nm; emission: 340 nm) using a reference value for
healthy controls of 0.11360.06 mg/100 mL. Serum cystatin C
(CysC) levels were determined by immunonephelometry (N Latex
Cystatin CH, Dade Behring, Marburg, Germany). In order to
assess the true GFR in non-dialyzed patients as accurately as
possible, the estimated GFR combining Scr and CysC measure-
ments (CKD-epi) was calculated according to the following,
recently published ‘‘CKD-epi’’ equation [17]:
177.66Scr20.656CysC20.576age20.206 (0.82 if female). For de-
scriptive purposes, patients were then classified into CKD stages,
according to the National Kidney Foundation’s Kidney Disease
Outcomes Quality Initiative guidelines [18].
Pulse Wave Velocity Evaluation
The carotid-femoral PWV was determined automatically with a
dedicated device with two pressure probes (Complior Colson,
Createch Industrie, Massy, France) and operated by a trained
physician, as previously described [19]. Transcutaneously record-
ed pulse waveforms were obtained simultaneously for the common
carotid artery and the femoral artery in the groin. The PWV was
calculated as the distance between recording sites measured over
the body’s surface (L), divided by the time interval (t) between the
feet of the flow waves (PWV=L/t); this value was averaged over
10 cardiac cycles [20]. This automated method has been validated
previously and has an intra-observer repeatability coefficient of
0.93 and an interobserver reproducibility coefficient of 0.89
[19,20].
Figure 3. Linear regression curves showing the relationship between free p-cresylglucuronide serum levels and free p-cresylsulfate
serum levels; r2 =0.95, p,0.0001.
doi:10.1371/journal.pone.0067168.g003
Table 3. Serum concentrations of p-cresylglucuronide and p-
cresylsulfate (total, free and bound) in the study population.
p-cresylglucuronide p-cresylsulfate
total (mg/dl) 0.2960.58 1.9461.84
free (mg/dl) 0.2760.54 0.2660.51
bound (mg/dl) 0.0360.05 1.6461.39
% protein bound 9.3067.3 91.40610.96
doi:10.1371/journal.pone.0067168.t003
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Abdominal Aorta Imaging with Plain Radiography
A technique similar to that described by Kauppila et al. [21]
was used to obtain images of the lower abdominal aorta and
generate an aortic calcification score. All X-rays were reviewed by
two independent investigators and a consensus on the interpreta-
tion was reached in all cases [22].
Multislice Spiral Computed Tomography
In order to quantify the presence and extent of aortic
calcifications, each patient underwent a MSCT scan. All
examinations were performed with a 64-detector scanner (Light-
speed VCTH, GE Healthcare, Milwaukee, WI, USA).
The volume acquisition started at the aortic hiatus of the
diaphragm and ended at the third lumbar vertebra. The scanning
parameters were as follows: collimation: 6460.625 mm; slice
thickness: 0.625 mm; pitch: 1; gantry rotation speed: 0.5 s/
rotation; tube voltage: 120 kV; tube current: 300 mA.
The volume acquisition was analyzed with commercially
available software (Volume ViewerH software, GE Healthcare,
Milwaukee, USA). The abdominal aorta was segmented manually.
In order to reduce errors due to noise, a threshold of 160 UH was
applied. The total calcification volume was calculated as the sum
of all voxels in the remaining volume. The abdominal aorta
Figure 4. Mortality and free p-cresylglucuronide levels (A) Kaplan–Meier estimates of overall mortality as a function of free p-
cresylglucuronide levels relative to the median; p=0.002 in a log-rank comparison of the curves. (B) Kaplan–Meier estimates of
cardiovascular mortality as a function of free p-cresylglucuronide levels relative to the median; p = 0.01 in a log-rank comparison of the curves.
doi:10.1371/journal.pone.0067168.g004
Figure 5. Harrell’s C index according to the Cox models (Model
1: Ln free PCS+aortic calcification+CRP+Hb; Model 2: Ln free IS
+aortic calcification+CRP+Hb; Model 3: Ln free PCG +aortic
calcification+CRP+Hb).
doi:10.1371/journal.pone.0067168.g005
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calcification score was calculated as follows: [(total calcification
volume)/(aorta wall surface area) * 100)].
Survival
Death records were established prospectively, by considering all
patients included at least twenty months before the study end date
(March 1, 2009). Each medical chart was reviewed and the cause
of death was assigned by a physician on the basis of all the
available clinical information. For out-of-hospital deaths, the
patient’s general practitioner was interviewed to obtain pertinent
information on the cause. Cardiovascular mortality was defined as
any death directly related to cardiovascular system dysfunction
(stroke, myocardial infarction, congestive heart failure or sudden
death).
Statistical Analyses
Data are expressed as either the mean 6 SD, the median or the
frequency, as appropriate. Percent binding was calculated as total
compound minus free compound divided by total compound
*100. For descriptive and analytical purposes, the study population
was stratified according the median serum free PCG concentration
(i.e. serum free PCG #0.041 mg/dl vs. serum free PCG
.0.041 mg/dl). Intergroup comparisons were performed using a
x2 test for categorical variables and Student’s t test or the Mann-
Whitney test for continuous variables. For variables with a non-
Gaussian distribution, log-normalized values were considered in
tests that assumed normally distributed variables. A Kaplan-Meier
actuarial curve was used to estimate overall and cardiovascular
mortality. The log-rank test was used to compare the survival
curves. Univariate and multivariate analyses of mortality were
performed by using a Cox proportional hazards model of death as
a function of free PCG levels as a continuous variable. In the
multivariate analysis, the predefined models included variables
found to be significantly associated with death in the univariate
analyses (age, hemoglobin, CRP, aortic calcification score, eGFR
and free PCG). As we did not use the backward selection option,
we limited the number of variables for adjustment as a function of
the number of events and created different models to include all
the cited variables. Given that levels of the three uremic toxins
evaluated here (PCS, PCG and IS) were highly intercorrelated
(r2 = 0.95 free PCS and free PCG, r2 = 0.73 free PCG and free IS
Table 4. Univariate and multivariate Cox regression analysis
of risk factors at baseline for all-cause mortality, with free p-
cresylglucuronide entered as a continuous variable in all
patients (n = 139).
Models of patient survival
(event n=38) RR 95% CI p
Unadjusted
Ln free p-cresylglucuronide 1.335 1.095–1.628 0.004
Model adjusted for age and hemoglobin
Ln free p-cresylglucuronide 1.32 1.05–1.64 0.015
Age 1.05 1.02–1.08 0.003
Hemoglobin 0.74 0.61–0.89 0.002
Model adjusted for age and CRP
Ln free p-cresylglucuronide 1.42 1.15–1.76 0.001
Age 1.05 1.02–1.09 0.002
CRP 1.007 0.99–1.02 0.073
Model adjusted for age and the aortic calcification score
Ln free p-cresylglucuronide 1.37 1.09–1.72 0.007
Age 1.04 0.99–1.08 0.07
Aortic calcification score 1.15 1.03–1.29 0.01
RR: risk ratio; CI: confidence interval.
doi:10.1371/journal.pone.0067168.t004
Table 5. Univariate and multivariate Cox regression analyses
of risk factors at baseline for cardiovascular mortality, with
free p-cresylglucuronide entered as a continuous variable in
all patients (n = 139).
Models of patient survival
(event n=22) RR 95% CI p
Unadjusted
Ln free p-cresylglucuronide 1.85 1.08–1.61 0.003
Model adjusted for age*
Ln free p-cresylglucuronide 1.80 1.01–3.21 0.046
Model adjusted for hemoglobin**
Ln free p-cresylglucuronide 1.98 1.11–3.52 0.021
Model adjusted for CRP
Ln free p-cresylglucuronide 2.24 1.22–4.10 0.0009
CRP 1.02 1.00–1.05 0.038
Model adjusted for the aortic calcification score
Ln free p-cresylglucuronide 1.96 1.06–3.61 0.031
Aortic calcification score 1.21 1.02–1.42 0.026
RR: risk ratio; CI: confidence interval.
*age was not significant after adjustment.
**hemoglobin was not significant after adjustment.
doi:10.1371/journal.pone.0067168.t005
Table 6. Univariate and multivariate Cox regression analysis
of risk factors at baseline for all-cause mortality, with free p-
cresylglucuronide entered as a continuous variable in the
predialysis population (n = 96).
Models of patient survival
(event n=18) RR 95% CI p
Unadjusted
Ln free p-cresylglucuronide 1.98 1.11–3.53 0.021
Model adjusted for age
Ln free p-cresylglucuronide 1.81 1.01–3.21 0.04
Age 1.05 1.00–1.09 0.05
Model adjusted for hemoglobin*
Ln free p-cresylglucuronide 1.78 1.01–3.21 0.04
Model adjusted for CRP
Ln free p-cresylglucuronide 2.20 1.20–4.02 0.01
CRP 1.02 1.00–1.05 0.05
Model adjusted for the aortic calcification score
Ln free p-cresylglucuronide 1.89 1.01–3.50 0.04
Aortic calcification score 1.6 1.01–2.61 0.04
Model adjusted for eGF **
Ln free p-cresylglucuronide 1.98 1.11–3.51 0.02
RR: risk ratio; CI: confidence interval.
*hemoglobin was not significant after adjustment.
**eGFR was not significant after adjustment.
doi:10.1371/journal.pone.0067168.t006
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and r2 = 0.72 free IS and free PCS), we never included them all in
the same model (i.e. to avoid colinearity bias). Hence, we used the
Akaike information criterion (AIC) and the C-Index to evaluate
the model’s power to predict mortality with each of the three
uremic toxins in turn. Given that the respective impacts of PCS
and IS on mortality have already been evaluated in the same
cohort, we compared the predictive power of three different Cox
models: free PCS+other risk factors, free IS+ other risk factors and
free PCG+other risk factors. The predictive power of the three
Cox models was assessed with Harrell’s C-index [23]. Harrell’s C
index provides an estimate of the proportion of correct predictions,
i.e., the proportion of patients with better staging and who had
better survival. The C-index varies from 0.5 (no discrimination) to
1 (perfect discrimination).
A p value#0.05 was considered to be statistically significant. All
statistical analyses were performed using SPSS software (SPSS Inc,
Chicago, IL), version 13.0 for Windows (Microsoft Corp, Red-
mond, WA).
Results
Figure 1 illustrates the distribution of free PCG levels by CKD
stage. Serum levels of free PCG increase with the severity of CKD
and were significantly higher in hemodialysis patients. When
considering non-dialyzed patients only (n = 96), we observed a
significant, inverse association between free PCG and the GFR, as
illustrated in Figure 2. The same profile was found for total PCG
(data not shown).
Table 1 and Table 2 depict the demographic, clinical and
biochemical characteristics of the 139 analyzed patients according
to the median free PCG level (total PCG #0.041 mg/dl vs. total
PCG .0.041 mg/dl). The patients with higher free PCG serum
levels had a lower body mass index and a more severe CKD
stages. Concerning vascular parameters, patients with free PCG
.0.041 mg/dl had a significantly higher aortic calcification score,
whereas the two groups did not differ significantly in terms of
PWV. Indeed, we found significant correlations between the aortic
calcification score and free PCG (r = 0.30 p= 0.001) and between
the coronary calcification score and free PCG (r = 0.24 p= 0.02).
Regarding biochemical parameters, patients with a higher free
PCG had higher serum phosphate, iPTH, free PCS, free IS, total
PCG, percentage PCG protein binding, lower hemoglobin levels
and GFR-epi. There were no differences in terms of total PCG or
free PCG when we divided the population according to diabetes
status (n = 59 diabetic patients).
Table 3 compares the serum levels of PCS and PCG; the total
mean concentration of PCS is substantially higher than that of
PCG, whereas the free levels are similar. The conjugates differed
markedly in terms of the percentage bound to protein
(91.4610.9% for PCS vs. only 9.367.3% for PCG). Furthermore,
the respective levels of PCS and PCG were highly correlated, with
r2 = 0.95 for the free fraction (Figure 3) and r2 = 0.51 for the total
concentration (data not shown).
During the study period (mean follow-up duration: 7796185
days; median (range): 815 (10–1129), 38 patients died (22 from
CV causes, 8 from infectious disease and 8 from other causes). In a
crude analysis (Figure 4), free PCG .0.041 mg/dl was a
significant predictor of overall and cardiovascular death (log-rank
comparison of the curves: p = 0.002 and p=0.01 respectively).
In a univariate Cox regression analysis, free IS, free PCS, total
PCG, free PCG, age, dialysis status, albumin, hemoglobin, C-
reactive protein and the aortic calcification score and eGFR (for
predialysis patients) were all significantly associated with the risk of
death (data not shown).
Table 4 shows the predictive power of free PCG levels for
death in unadjusted models or models adjusted for multiple
covariates. After adjusting the different models for age, hemoglo-
bin, C-reactive protein and the aortic calcification score, higher
serum levels of free PCG still had a significant effect on the risk of
death. It is noteworthy that high levels of free PCG were also
independently associated with cardiovascular mortality, as shown
in Table 5. These results were confirmed when the crude analysis
was restricted to CKD pre-dialysis patients (n = 96, deaths = 18)
and after adjustment for the same covariables and eGFR
(Table 6). The univariate Cox model’s ability to predict the
mortality associated with each of the three uremic toxins was
estimated by calculation of the Akaike information criterion (AIC),
with values of 350, 349 and 352 for PCS, PCG and IS,
respectively. In addition, Figure 5 shows Harrell’s C index for
three multivariate models including aortic calcification score,
CRP, hemoglobin and, respectively, free PCS, free IS and free
PCG. Harrell’s C index [95%CI] was 0.77 [0.68–0.95] for the free
PCS model; 0.73 [0.64–0.82] for the free IS model and 0.74
[0.64–0.83] for the free PCG model). The similar values of
Harrell’s C index suggest that the three variables do not differ
significantly in terms of predictive performance.
Discussion
Our study demonstrated that both total and free PCG levels
were rose with the decrease of GFR and are increased in
hemodialysis patients. More importantly, free and total PCG levels
were associated with total and cardiovascular mortality. Moreover,
it appears that the three uremic toxins investigated (PCS, PCG
and IS) were able to predict mortality in the present cohort to the
same extent.
Firstly, in a large cohort of patients at various CKD stages, we
confirmed that the serum concentration of PCG is elevated, as also
recently reported [12] in a smaller group of uremic dialysis
patients. We also found an inverse relationship between free/total
PCG levels and the glomerular filtration rate, with toxin
accumulation greatest in patients on dialysis. It has been
demonstrated that conjugation of p-cresol results in high
concentrations of PCS (as the main metabolite) and markedly
lower concentrations of total PCG [9,12]. We confirmed this
finding, as levels of total PCS were approximately 7-fold higher
than those of total PCG in our cohort (as shown in Table 3).
However, the conjugates showed a marked difference in percent-
age binding to protein, with high values for PCS (91.4610.9%)
and low ones for PCG (9.367.3%). However, although most of
PCS is bound whereas PCG to the largest extent is free, their
absolute free concentrations appear to be identical. Our present
results differ from those of Berge´-Lefranc et al., who reported
substantially higher free PCS levels. However, the latter authors
used isothermal titration calorimetry to assay for PCS; this
methodological difference may explain the disparities in the results
[24]. However, Itoh et al. [25] recently used a newly developed
method (involving simultaneous LC/ESI-MS/MS) to determine
levels of PCS binding that were similar to those observed here,
whereas PCG binding was higher than in the present study.
Secondly, we demonstrated that serum PCG levels were
associated with increased aortic calcification in the study cohort,
since we observed a positive correlation between serum PCG levels
and the aortic/coronary calcification scores. Recent research has
revealed how some uremic toxins (including PCS and IS) can
produce toxic biological effects. However, to the best of our
knowledge, the impact of PCG on vascular calcification has not yet
been evaluated. Recently published data show that indoxylglucur-
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onides (such as IS) can induce reactive oxygen species production
in human umbilical vein endothelial cells [25]. Furthermore,
oxidative stress has been linked to vascular calcification [26]. We
are now actively working to investigate this issue.
Lastly, we have shown for the first time that higher free and
total PCG concentrations were associated with mortality,
independently of well-known predictors of survival (such as age,
vascular calcification, anemia, inflammation and eGFR for
predialysis patients). These results are in line with previous reports
on the mother compound, p-cresol [27,28]. Overall, studies in
CKD cohorts have found a negative impact of free (but not total)
p-cresol/PCS on the relative risk of mortality [14,28–30]. In
contrast to the findings for p-cresol/PCS, we demonstrated that
the clinical impact of PCG is relevant for both free and total
fractions. The protein-bound fraction of PCG is low so that free
and total concentrations are much closer to each other than is the
case for PCS. Therefore, one can legitimately assume that the total
and free PCG fractions should have similar weightings in outcome
studies. It is noteworthy than in our cohort of patients at different
stages of CKD, the free fractions of the three protein-bound
uremic toxins (PCS, PCG and IS) did not differ significantly in
terms of their respective abilities to predict mortality. Hence, these
uremic toxins may be potential therapeutic targets for preventing
renal complication. Indeed, the AST-120 oral charcoal adsorbent
(Kremezin, Kureha Chemical Industry, Tokyo, Japan) adsorbs
hydrophobic uremic toxins and has shown promise in animal
studies and epidemiologic surveys. Indeed, AST 120 has been
shown to attenuate the reduction in estimated creatinine clearance
in CKD patients [31] and improve uremic syndrome [32].
Beneficial impacts on cardiovascular and bone complications have
also been suggested [33–34]. These beneficial effects has been
attributed to its action on IS and PCS levels, but potential effects
on PCG although possible did not yet explored.
The present study’s limitations include the relatively small
sample size and the small number of protein-bound uremic toxins
assayed simultaneously. However, PCS and IS are the most
frequently studied compounds within this group of uremic toxins.
In contrast, the study’s main strengths are (i) the inclusion of
patients at different CKD stages, (ii) the application of a novel
analytical method for assaying both the major and the minor
conjugate of p-cresol (since data on the latter had been lacking
until now).
In conclusion, this is the first study to have evaluated free and
total levels of PCG – a hitherto neglected in vivo metabolite of p-
cresol - in patients at different stages of CKD. Our data emphasize
the significance of free and total PCG as predictors of survival,
despite the fact that the compound is only a minor metabolite of p-
cresol. However, future research must further elucidate the role of
PCG and confirm that uremic toxins that can bind to protein are
interchangeable biomarkers of mortality.
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